IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
about
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsPD-1 and its ligands are important immune checkpoints in cancerThe role of immune checkpoint inhibition in the treatment of ovarian cancerEnhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control.A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitisInhibitory receptors as targets for cancer immunotherapySuppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancerAnti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.IL-27 induces the expression of IDO and PD-L1 in human cancer cells.EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancersHigh-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cellsChemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia.Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma.Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognosticROS mediates interferon gamma induced phosphorylation of Src, through the Raf/ERK pathway, in MCF-7 human breast cancer cell lineRational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy.Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.Targeting metastasis.Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.Programming the immune checkpoint to treat hematologic malignancies.JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
P2860
Q26797478-6EC1396C-CC12-4646-A109-313C4127ADB5Q28069485-B3F69DAA-F0F6-44FA-9C2A-FC7CEC6623B3Q28077924-8271E879-CB05-46B2-8799-4E6565AFCB89Q33276035-019E71D1-F3E9-485E-91A1-4C057BA185F2Q33607407-EB18D8C1-B222-4B35-8584-B70D9C3AF38FQ33648621-424AB7F2-1450-4E64-ABAF-85757C1F76EFQ33688821-18B1211B-6EB1-47F2-9772-0C51D0BAA6CDQ33822472-8D3DB7DE-CC0B-47D7-A501-DB7405A24833Q33909697-3E3E974B-8BA5-4E4C-99A5-2ECE56285980Q35995373-36285F30-9856-4A13-80E3-D9C71E1F9054Q36057092-E4CC455F-19CF-4FAD-B4FF-E6257DF5A359Q36173622-1EBF752E-E5AA-4F6C-9549-39A17C7A4677Q36553576-003BC18F-AE86-4465-B6E5-FA10496B2535Q36685395-7D3A41A6-2BC1-47A2-BA44-5F2A17F22911Q36821217-DF277F79-CCDA-44FA-833B-8E3B68632FD3Q36939402-2C58386A-F97D-4456-A06C-5EB5E5F058B5Q37346163-C58AF119-BA63-4417-B12C-44DAA7B00E95Q37376726-CB53D154-824A-40D2-8178-398A0F0E18DDQ37525422-8FC2F8D6-3866-45F9-8742-D860EDF576E2Q37641560-748B23AA-F9CE-4268-9A33-9742D2BE7278Q37641608-30685DB1-8E2A-422F-9EB5-3DFB757BEC36Q37650062-DD68DF08-B279-4163-9941-C0AA3EB341DCQ37713503-0A4023B0-D00D-447F-A1CC-AC8F327DF33AQ37716378-30DB9FAC-E06E-487C-ADC7-A78BEC85F563Q37716710-80FE1EA5-E220-40D7-962D-488495DC976BQ37736296-161D8D83-FEA3-4EFB-820B-E364DD9D6F05Q38401891-FDB17452-B317-4C2C-A3D7-5DCA9D28ADE5Q38659916-631412EE-BB62-4768-9624-0E121632A39BQ38696547-BAC1B3EB-725D-4EDF-9167-1DA149B4BD0EQ38709131-CAA3E47F-E7F0-413D-B6FB-214F6F6C2C04Q38730989-0F4F6DAF-3F6C-453F-BC65-E91077E3CBE6Q38770458-FF1F249C-F62C-4A25-977F-812DF599B4D5Q38786658-BE97D82A-6009-4F84-A1C9-5D17035769FFQ38801345-12090B30-C434-47F0-9F3C-10CC4F7A1A36Q38806070-1EC76705-95DC-4553-BDA8-45A1DFD8C727Q38839108-9DE9B89E-681A-40CC-90FB-6A5C12F6D272Q38910078-EABBD6F2-E3A2-48D8-859D-41D00B70605DQ38962024-24E86B77-A28E-4F5F-8150-C79524BFCE60Q38998427-CD520A34-1E84-455F-869C-2A8C28A7140FQ39003387-EDE3342F-637E-45B4-9768-B3138784B377
P2860
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
IFN-γ from lymphocytes induces ...... progression of ovarian cancer.
@ast
IFN-γ from lymphocytes induces ...... progression of ovarian cancer.
@en
type
label
IFN-γ from lymphocytes induces ...... progression of ovarian cancer.
@ast
IFN-γ from lymphocytes induces ...... progression of ovarian cancer.
@en
prefLabel
IFN-γ from lymphocytes induces ...... progression of ovarian cancer.
@ast
IFN-γ from lymphocytes induces ...... progression of ovarian cancer.
@en
P2093
P2860
P356
P1476
IFN-γ from lymphocytes induces ...... progression of ovarian cancer
@en
P2093
J Hamanishi
N Horikawa
R Murakami
Y Yoshioka
P2860
P2888
P304
P356
10.1038/BJC.2015.101
P407
P577
2015-03-31T00:00:00Z